

References

S-275

1. Parsons JK, Barry MJ, Dahm P, et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline. 2020.
2. Tanneru K, Gautam S, Norez D, et al. Meta-analysis and systematic review of intermediate-term follow-up of prostatic urethral lift for benign prostatic hyperplasia. *Int Urol Nephrol*. 2020;52(6):999-1008.
3. Sievert KD, Schonthaler M, Berges R, et al. Minimally invasive prostatic urethral lift (PUL) efficacious in TURP candidates: A multicenter German evaluation after 2 years. *World J Urol*. 2019;37(7):1353-1360.
4. Jung JH, Reddy B, McCutcheon KA, et al. Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. *Cochrane Database Syst Rev*. 2019;25;5(5):CD012832.
5. Miller LE, Chughtai B, Dornbier RA, et al. Surgical reintervention rate after prostatic urethral lift: Systematic review and meta-analysis involving over 2,000 patients. *J Urol*. 2020;204(5):1019-1026.
6. Rukstalis D, Grier D, Stroup SP, et al. Prostatic urethral lift (PUL) for obstructive median lobes: 12-month results of the MedLift Study. *Prostate Cancer Prostatic Dis*. 2019;22(3):411-419.
7. Eure G, Gange S, Walter P, et al. Real-world evidence of prostatic urethral lift confirms pivotal clinical study results: 2-year outcomes of a retrospective multicenter study. *J Endourol*. 2019;33(7):576-584.
8. National Institute for Health and Care Excellence (NICE). Prostate cancer: Diagnosis and management. [NG131]. 2019.
9. Kang TW, Jung JH, Hwang EC, et al. Convective radiofrequency water vapour thermal therapy for lower urinary tract symptoms in men with benign prostatic hyperplasia. *Cochrane Database Syst Rev*. 2020;25;3(3):CD013251.
10. McVary KT, Rogers T, Roehrborn CG. Rezūm water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4-year results from randomized controlled study. *Urology*. 2019;126:171-179.
11. Hayes, Inc. Health Technology Assessment. *Prostatic Urethral lift (UroLift System) for Treatment of Symptoms Associated with Benign Prostatic Hyperplasia*. Lansdale, PA: Hayes, Inc.; 06/09/2020.
12. Zhang F, Shao Q, Du Y, et al. Evaluation of 24-core coaxial needle saturation biopsy of the prostate by the transperineal approach in detecting prostate cancer in patients without previous biopsy history: A single center reports. *J Can Res Ther*. 2019;15:380-5.
13. Hayes, Inc. Hayes Evidence Analysis Research Brief. *Transperineal Template Biopsy for Detection of Prostate Cancer in Patients with Previous Negative Transrectal Biopsy*. Lansdale, PA: Hayes, Inc.; 10/31/2019.
14. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. v.3.2022.

15. Liu G, Yan T. Pelvic phased-array mpMRI versus saturation biopsy: A diagnostic performance analysis in men with suspected advanced prostate cancer. *Scand J Urol*. 2020;54(1):14-19.
16. Amin A, Scheltema MJ, Shnier R, et al. The magnetic resonance imaging in active surveillance (MRIAS) trial: Use of baseline multiparametric magnetic resonance imaging and saturation biopsy to reduce the frequency of surveillance prostate biopsies. *J Urol*. 2020;203(5):910-917.
17. Pepe P, Pennisi M, Fraggetta F. How many cores should be obtained during saturation biopsy in the era of multiparametric magnetic resonance? Experience in 875 patients submitted to repeat prostate biopsy. *Urology*. 2020;137:133-137.
18. Schörghofer A, Drerup M, Kunit T, et al. Rectum-spacer related acute toxicity - endoscopy results of 403 prostate cancer patients after implantation of gel or balloon spacers. *Rad Oncol (London, England)*. 2019;14(1):47.
19. Hayes Health Technology Brief. *Absorbable Perirectal Spacer (Spaceoar System; Augmenix inc.) During Radiation Therapy for Prostate Cancer*. Lansdale, PA: Hayes, Inc; 4/10/2021.
20. Miller LE, Efsthathiou JA, Bhattacharyya SK, et al. Association of the placement of a perirectal hydrogel spacer with the clinical outcomes of men receiving radiotherapy for prostate cancer: A systematic review and meta-analysis. *JAMA Netw Open*. 2020;1;3(6):e208221.
21. Lerner LB, McVary KT, Barry MJ, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline part I, initial work-up and medical management. *J Urol*. 2021;206:806.
22. Lerner LB, McVary KT, Barry MJ, et al: Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline part II, surgical evaluation and treatment. *J Urol*. 2021;206:818.
23. Page T, Veeratterapillay R, Keltie K, et al. Prostatic urethral lift (UroLift): A real-world analysis of outcomes using hospital episodes statistics. *BMC Urol*. 2021;21(1):55.
24. National Institute for Health and Care Excellence (NICE). UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia [MTG58]. 2021.
25. McVary KT, Gittelman MC, Goldberg KA, et al. Final 5-Year outcomes of the multicenter randomized sham-controlled trial of a water vapor thermal therapy for treatment of moderate to severe lower urinary tract symptoms secondary to benign prostatic hyperplasia. *J Urol*. 2021;206(3):715-724.
26. Gilling P, Barber N, Bidair M, et al. Three-year outcomes after aquablation therapy compared to TURP: Results from a blinded randomized trial. *Can J Urol*. 2020;27(1):10072-10079.
27. Hwang EC, Jung JH, Borofsky M, et al. Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. *Cochrane Database Syst Rev*. 2019;2(2):CD013143.
28. National Institute for Health and Care Excellence. Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia. 2020.
29. Chin JL, Lavi A, Metcalfe MJ, et al. Long-term outcomes of whole gland salvage cryotherapy for locally recurrent prostate cancer following radiation therapy: A combined analysis of two centers. *J Urol*. 2021;206(3):646-654.

30. Bates AS, Ayers J, Kostakopoulos N, et al. A systematic review of focal ablative therapy for clinically localised prostate cancer in comparison with standard management options: Limitations of the available evidence and recommendations for clinical practice and further research. *Eur Urol Oncol*. 2021;4(3):405-423.
31. Mehralivand S, George AK, Hoang AN, et al. MRI-guided focal laser ablation of prostate cancer: A prospective single-arm, single-center trial with 3 years of follow-up. *Diagn Interv Radiol*. 2021;27(3):394-400.
32. Chao B, Lepor H. 5-Year Outcomes following focal laser ablation of prostate cancer. *Urology*. 2021;155:124-129.
33. Nahar B, Bhat A, Reis IM, et al. Prospective evaluation of focal high intensity focused ultrasound for localized prostate cancer. *J Urol*. 2020;204(3):483-489.
34. Babar M, Katz A, Ciatto M. Dosimetric and clinical outcomes of SpaceOAR in men undergoing external beam radiation therapy for localized prostate cancer: A systematic review. *J Med Imaging Radiat Oncol*. 2021;65(3):384-397.
35. Te Velde BL, Westhuyzen J, Awad N, et al. Late toxicities of prostate cancer radiotherapy with and without hydrogel SpaceAOR insertion. *J Med Imaging Radiat Oncol*. 2019;63(6):836-841.
36. Seymour ZA, Hamstra DA, Daignault-Newton S, et al. Long-term follow-up after radiotherapy for prostate cancer with and without rectal hydrogel spacer: A pooled prospective evaluation of bowel-associated quality of life. *BJU Int*. 2020;126(3):367-372.
37. Chao M, Ow D, Ho H, et al. Improving rectal dosimetry for patients with intermediate and high-risk prostate cancer undergoing combined high-dose-rate brachytherapy and external beam radiotherapy with hydrogel spacer. *J Contemp Brachytherapy*. 2019;11(1):8-13.
38. Kahn J, Dahman B, McLaughlin C, et al. Rectal spacing, prostate coverage, and periprocedural outcomes after hydrogel spacer injection during low-dose-rate brachytherapy implantation. *Brachytherapy*. 2020;19(2):228-233.
39. Nehlsen AD, Sindhu KK, Moshier E, et al. The impact of a rectal hydrogel spacer on dosimetric and toxicity outcomes among patients undergoing combination therapy with external beam radiotherapy and low-dose-rate brachytherapy. *Brachytherapy*. 2021;20(2):296-301.
40. Butler WM, Kurko BS, Scholl WJ, et al. Effect of the timing of hydrogel spacer placement on prostate and rectal dosimetry of low-dose-rate brachytherapy implants. *J Contemp Brachytherapy*. 2021;13(2):145-151.
41. Hayes, Inc. Health Technology Assessment. *Ultrasound-Guided High-Intensity Focused Ultrasound for Primary Treatment of Localized Prostate Cancer*. Lansdale, PA: Hayes, Inc.; 11/22/2022.
42. Eure G, Rukstalis D, Roehrborn C. Prostatic urethral lift for obstructive median lobes: Consistent results across controlled trial and real-world settings. *J Endourol*. 2023 Jan;37(1):50-59.
43. Hopstaken JS, Bomers JGR, Sedelaar MJP, et al. An updated systematic review on focal therapy in localized prostate cancer: What has changed over the past 5 years? *Eur Urol*. 2022 Jan;81(1):5-33.
44. Duwe G, Boehm K, Haack M, et al. Single-center, prospective phase 2 trial of high-intensity focused ultrasound (HIFU) in patients with unilateral localized prostate cancer: Good functional results but oncologically not as safe as expected. *World J Urol*. 2023 May;41(5):1293-1299.

45. Khan A, Khan AU, Siref L, et al. Focal cryoablation of the prostate: Primary treatment in 163 patients with localized prostate cancer. *Cureus*. 2023;15(4):e37172.
46. Vaggers S, Rai BP, Chedgy ECP, et al. Polyethylene glycol-based hydrogel rectal spacers for prostate brachytherapy: A systematic review with a focus on technique. *World J Urol*. 2021 Jun;39(6):1769-1780.
47. Jung JH, McCutcheon KA, Borofsky M, et al. Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. *Cochrane Database Syst Rev*. 2022;3(3):CD012867.